AACR: Colon Cancer Patients Respond to Antibody/KRAS Inhibitor Combo

1 year ago 35

Colorectal cancer therapy, a combination of adagrasib plus cetuximab, shows antitumor activity in a Phase I/II trial, heads to Phase III